Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Unit Of Sanofi-Aventis Told By WHO 5-Disease Vaccine Has Problem

This article was originally published in PharmAsia News

Executive Summary

The Indian subsidiary of French drug maker Sanofi-Aventis has been told by the United Nations it was suspending purchase and use of the Shan5 vaccine for five diseases, including tetanus

You may also be interested in...



WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010

MUMBAI - French drug maker Sanofi Aventis is faced with an unexpected crisis situation over large quantities of product recall ordered by the World Health Organization for pediatric pentavalent vaccines manufactured by its newly acquired Indian vaccines unit - Shantha Biotechnics

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

UsernamePublicRestriction

Register

SC074303

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel